+

WO1996030762A1 - Methode d'identification de composes imitant et amplifiant l'action de l'insuline - Google Patents

Methode d'identification de composes imitant et amplifiant l'action de l'insuline Download PDF

Info

Publication number
WO1996030762A1
WO1996030762A1 PCT/US1996/004226 US9604226W WO9630762A1 WO 1996030762 A1 WO1996030762 A1 WO 1996030762A1 US 9604226 W US9604226 W US 9604226W WO 9630762 A1 WO9630762 A1 WO 9630762A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
compounds
cells
receptor
activity
Prior art date
Application number
PCT/US1996/004226
Other languages
English (en)
Inventor
Bei Zhang
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to JP8529629A priority Critical patent/JPH11503519A/ja
Priority to EP96910609A priority patent/EP0817967A4/fr
Publication of WO1996030762A1 publication Critical patent/WO1996030762A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Definitions

  • the invention relates to insulin mimetic and enhancer agents and more specifically to methods of identifying compounds that mimic and enhance insulin action and compounds identified by the method.
  • Insulin is a hormone that is necessary for normal carbohydrate, protein, and fat metabolism in mammals. People with insulin-dependent (Type I) diabetes mellitus do not produce enough insulin of this hormone to sustain life and, therefore, depend on exogenous insulin for survival. In contrast, individuals with non- insulin-dependent (Type II) diabetes are not dependent on exogenous insulin for survival. However, over time, many of individuals with type II diabetes show decreased insulin production, which requires supplemental insulin for adequate blood glucose control, especially during times of stress or illness. An exogenous insulin regimen is often required in the treatment of secondary diabetes, i.e., diabetes occurring in relation to other disease states such as pancreatic disease. Insulin is also used in some cases of gestational diabetes to obtain optimum blood glucose control.
  • the conventional route of insulin administration is via a needle and syringe.
  • Continuous subcutaneous insulin infusion with an infusion pump is an alternative to conventional injection therapy for achieving normalized levels of blood glucose.
  • Insulin initiates its metabolic and growth promoting effects upon binding to its tetrameric receptor. The binding activates a kinase in the beta -subunit, which catalyzes the intramolecular autophosphorylation of specific tyrosine residues of its own ⁇ -subunits. Autophosphorylation enhances tyrosine kinase activity toward other protein substrates.
  • insulin receptor tyrosine kinase activity is essential for many, if not all of the biological effects of insulin.
  • the precise biochemical mechanisms linking receptor kinase-mediated tyrosine phosphorylation to the regulation of cellular metabolic pathways are not completely defined.
  • the instant invention is a novel assay to identify insulin mimetic and enhancer compounds.
  • the assay is designated as the Insulin Mimetic and Enhancer ⁇ s ay.
  • the purpose of the IMA-II is to discover nonpeptide, small molecules that may be developed into insulin mimetic and enhancer agents.
  • the assay is based on insulin receptor tyrosine phosphorylation, and activation of the receptor tyrosine kinase events immediately downstream of insulin stimulation.
  • Chinese Hamster Ovary (CHO) cells expressing human insulin receptor are plated and treated with insulin or test agents.
  • CHO.T cells are one type of CHO cells that express human insulin receptor. The treated cells are lysed, and the insulin receptor is purified.
  • the level of tyrosine phosphorylation of the receptor is determined using an anti- phosphotyrosine antibody conjugated to alkaline phosphatase and its chromogenic substrate.
  • the insulin receptor tyrosine kinase activity (IRTK) is determined using an exogenous substrate and ⁇ -32p-ATP. The assay facilitates rapid screening and high throughput of test compounds.
  • the invention relates to insulin mimetic and enhancer and enhance agents and more specifically to methods of identifying compounds that mimic and enhance insulin action and compounds identified by the method.
  • FIG 1 shows the scheme of insulin mimetic and enhancer assay.
  • Figure 2 shows the activation of IRTK by insulin in CHO.T cells.
  • Figure 3 shows the activation of IRTK by a natural product (N-400306).
  • Figure 4 shows the enhancement of insulin stimulation of IRTK by a natural product (N-400306).
  • the invention relates to insulin mimetic and enhancer agents and more specifically to methods of identifying compounds that mimic and enhance insulin action and compounds identified by the method. More specifically, the instant invention is a novel assay to identify insulin mimetic and enhancer compounds.
  • the assay is designated as the Insulin Mimetic and Enhancer Assay.
  • the purpose of the assay is to discover nonpeptide, small molecules that may be developed into insulin mimetic and enhancing agents.
  • the assay is based on insulin receptor tyrosine phosphorylation, and activation of the receptor tyrosine kinase events immediately downstream of insulin stimulation.
  • Chinese Hamster Ovary (CHO) cells expressing human insulin receptor (CHO-T) are plated and treated with insulin or test agents.
  • the treated cells are lysed, and the insulin receptor is purified.
  • the level of tyrosine phosphorylation of the receptor is determined using anti-phosphotyrosine antibody conjugated to alkaline phosphatase and its chromogenic substrate.
  • the IRTK activity is determined using an exogenous substrate and ⁇ -32p-ATP.
  • the assay is also performed by treating the cells with test agents in the presence of sub-maximal concentration of insulin, in an effort to identify insulin sensitigers. The assay facilitates rapid screening and high throughput of test compounds.
  • An insulin-related disease is a disease, disorder, or condition in which some aspect of insulin expression, metabolism, or action is disrupted or, a disease in which insulin action contributes to the disease.
  • An insulin resistant disease is any disease, disorder, or condition in which a normal amount of insulin results in a less than normal biological response. Examples of insulin- deficient diseases include Type I or insulin-dependent diabetes. Examples of insulin resistant diseases include Type II diabetes, obesity, age-related insulin resistance, and insulin resistance that arises secondary to infections, hormonal disorders, or other causes.
  • the invention includes a method of assaying an effect of a therapeutic agent on activation of insulin signal transduction in cells.
  • the method includes administering the agent to a test organism, e.g., a cultured cell or a mammal, and measuring the effect of the drug on an aspect of insulin receptor metabolism, e.g., measuring the level of the insulin receptor phosphorylation.
  • a change in an aspect of insulin receptor metabolism indicates an effect of the agent.
  • the invention includes a method of assaying an effect of a therapeutic agent which alters the ability of a tyrosine kinase to phosphorylate a substrate.
  • the method includes administering the drug to a test organism, e.g., a cultured cell or a mammal, and measuring the level of phosphorylation of a substrate.
  • the invention further includes a method of treating a mammal e.g.. a human, suffering from a disease caused by insulin deficiency or insulin resistance, e.g., Type I and Type II diabetes mellitus.
  • the method includes administering to the mammal a therapeutical ly effective amount of a therapeutic agent, e.g., agent which alters an aspect of the metabolism of insulin receptor, e.g., the level of insulin receptor phosphorylation, e.g., by increasing the activity of a kinase or decreasing the activity of a phosphatase.
  • a therapeutic agent e.g., agent which alters an aspect of the metabolism of insulin receptor, e.g., the level of insulin receptor phosphorylation, e.g., by increasing the activity of a kinase or decreasing the activity of a phosphatase.
  • Methods of the invention also allow the treatment of a variety of diseases, e.g., insulin related diseases, insulin resistant diseases, diseases characterized by abnormal cellular proliferation, and diseases caused by the phosphorylation of a substrate by a tyrosine kinase, by intervening in aspects of insulin receptor metabolism.
  • diseases e.g., insulin related diseases, insulin resistant diseases, diseases characterized by abnormal cellular proliferation, and diseases caused by the phosphorylation of a substrate by a tyrosine kinase, by intervening in aspects of insulin receptor metabolism.
  • the present invention provides methods of identifying compounds that interact with insulin receptor.
  • Methods of identifying compounds are exemplified by an assay, comprising:
  • the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding genes regulated by insulin or which modulate the function of insulin regulated proteins.
  • Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non- proteinaceous organic molecules.
  • Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding genes regulated by insulin or the function of insulin regulated protein.
  • Compounds that modulate the expression of DNA or RNA encoding genes regulated by insulin or the function of insulin regulated protein may be detected by a variety of assays.
  • the assay may be a simple "yes/no" assay to determine whether there is a change in expression or function.
  • the assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample.
  • Kits containing the compounds that modulate DNA, RNA, antibodies to insulin regulated protein or insulin regulated protein may be prepared. Such kits are useful for a variety of purposes including but not limited to forensic, taxonomic or epidemiological studies.
  • Pharmaceutically useful compositions comprising modulators of insulin activity may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, or modulator.
  • compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders.
  • the effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
  • compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
  • chemical derivative describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, abso ⁇ tion, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
  • the present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
  • the compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration.
  • the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
  • they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the active agents can be administered concurrently, or they each can be administered at separately staggered times.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • the CHO.T cells of the present invention are available from Dr.
  • cell lines similar to the CHO.T cells used herein may be prepared by one skilled in the art.
  • NIH3T3 cells, COS cells, Rat-1 cells and other appropriate fibroblasts transfected with cDNA encoding human insulin receptor can also be used in this assay.
  • the present invention relates to novel modalities for treatment of diabetes, and other diseases caused by dysfunctional signal transduction by receptor type tyrosine kinases. in particular the insulin receptor.
  • the present invention further relates to methods for screening and identifying compounds capable of modulating the activity of insulin receptor tyrosine kinases.
  • Such compounds may be insulin mimetic or sensitizer, by interaction directly or indirectly with the receptor (e.g., through inhibition of insulin receptor specific tyrosine phosphatase).
  • Such compounds may be used in the treatment of diabetes and other diseases mediated by the insulin receptor type tyrosine kinases.
  • Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. The process is generally imitated by the binding of extracellular factors (such as hormones and growth factors) to membrane receptors on the cell surface.
  • extracellular factors such as hormones and growth factors
  • the biochemical pathways through which signals are transmitted within cells comprise a circuitry of directly or functionally connected interactive proteins. Each protein component in a pathway integrates signals from upstream activators and passes them onto various downstream effector proteins.
  • the phosphorylation state of a protein may affect its conformation and/or enzymic activity as well as its cellular location.
  • the phosphorylation state of a protein is modified through the reciprocal actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs).
  • PTKs protein tyrosine kinases
  • PTPs protein tyrosine phosphatases
  • Protein tyrosine kinases comprise a large family of transmembrane as well as cytoplasmic enzymes with multiple functional domains (Taylor et al., 1992 Ann. Rev. Cell Biol. 8:429-62).
  • RPTKs receptor protein tyrosine kinase
  • Receptor dimerization stabilizes the interactions between adjacent cytoplasmic domains, and activates the intrinsic kinase activity of the receptor. Once activated, the receptor self-phosphorylates (autophosphorylation or transphosphorylation) on specific tyrosine residues in the cytoplasmic domain (Schlessinger, 1988, Trends Biochem., Sci. 13:443-7, Schlessinger and Ullrich, 1992, Neuron, 9:383-91 , and references therein). In case of insulin receptor-type RPTKs, the receptor exists naturally as a dimer, undergoing a conformational change and autophosphorylation upon ligand binding.
  • RPTKs assume a key role in signal transduction, the part played by phosphatases remains poorly understood.
  • PTP protein tyrosine phosphatases
  • the protein tyrosine phosphatases comprise a family of transmembrane and cytoplasmic enzymes.
  • RPTKs play a triggering role in signal transduction, while RPTPs guarantee that the trigger is reset, thereby serving to deactivate the pathway.
  • the PTP specific for insulin receptor is not defined at present.
  • the insulin receptor (IR) (Ebina et al, 1985, Cell, 40, 747- 758; Ullrich et al, 1985, Nature 313:756-61 ) is the prototype for a family of RPTKs structurally defined as a heterotetrameric species of two ⁇ and two ⁇ subunits.
  • Other members of the insulin receptor-type protein tyrosine kinase (IR-PTK) family include the receptor for insulin-like growth factor I (IGF-1 R; Ullrich et al, 1986, EMBO J 5:2503-12) and the insulin related receptor (IRR; Zhang et al, 1992, J. Biol. Chem. 267: 18320-8), the ligand(s) for which are at present unknown.
  • Insulin binding to the insulin receptor triggers a variety of metabolic and growth promoting effects. Metabolic effects include glucose transport, biosynthesis of glycogen and fats, inhibition of triglyceride breakdown, and growth promoting effects include DNA synthesis, cell division and differentiation. It is known that some of these biological effects of insulin can be mimicked by vanadium salts such as vanadates and pervanadates. However, this class of compounds appears to inhibit phosphotyrosine phosphatases generally, and are potentially toxic because they contain heavy metal (U.S. Patent No. 5.155,031 ; Fantus et al, 1989, Biochem., 28:8864-71 ; Swamp et al, 1982, Biochem. Biophys. Res. Commun. 107:1 104-9).
  • Diabetes mellitus is a heterogeneous primary disorder of carbohydrate metabolism with multiple etiologic factors that generally involve insulin deficiency or insulin resistance or both.
  • Type I or juvenile onset, or insulin-dependent diabetes mellitus
  • Type II or adult onset, or non-insulin-dependent diabetes mellitus
  • Insulin resistance can be due to insufficient insulin receptor expression, reduced insulin-binding affinity, or any abnormality at any step along the insulin signaling pathway.
  • diabetes is probably between 2 and 4 per cent, with Type I comprising 7 to 10 per cent of all cases. Secondary complications of diabetes have serious clinical implications. Approximately 25 per cent of all new cases of end-stage renal failure occur in patients with diabetes. About 20,000 amputations (primarily of toes, feet, and legs) are carried out in patients with diabetes, representing approximately half of the nontraumatic amputations performed in the United States. Furthermore, diabetes is the leading cause of new cases of blindness, with approximately 5000 new cases occurring each year.
  • Insulin is the primary mode of therapy in all patients with Type I and in many with Type II diabetes.
  • the regimen can be more or less intensive.
  • the most intensive method consists of constant insulin delivery into a subcutaneous site in the abdominal wall via an open loop delivery device consisting of a small insulin pump that must be worn by the patient essentially 24 hours a day.
  • Oral hypoglycemic agents such as sulfonylureas are effective in Type II patients but approximately 10 to 20 percent of patients do not respond or cases to respond 12-24 months after beginning treatment.
  • the present invention relates to novel modalities for treatment of diabetes, and other diseases caused by dysfunctional signal transduction by the insulin receptor (IR) class of protein tyrosine kinases.
  • the present invention further relates to methods for screening and identifying compounds which mimic or enhance the ability of insulin to activate IRTK (insulin mimetic and enhancer assay) and thus have uses in the treatment of diabetes and other diseases.
  • the present invention relates to novel modalities for the treatment of diabetes, and other diseases caused by dysfunctional signal transduction by insulin receptor type protein tyrosine kinases (IR- PTKs).
  • IR- PTKs insulin receptor type protein tyrosine kinases
  • signal transduction is not limited to transmembrane signaling, and includes the multiple pathways that branch off throughout the cell and into the nucleus. Within each individual circuit of the pathway, protein tyrosine kinases and tyrosine phosphatases carry out a series of phosphorylation and dephosphorylation steps which serve to propagate or terminate the signal.
  • the present invention involves the use of compounds, antibodies, nucleic acid molecules or other approaches to modulate the activity of IRTK targets and, therefore, affect signal transduction.
  • compositions of the present invention in particular, those formulated as solutions, may be administered parenterally. such as by intravenous injection.
  • pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended pu ⁇ ose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
  • compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • compositions for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl- cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this pu ⁇ ose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture (i.e.. the concentration of the test compound which achieves a half -maximal inhibition of the PTP activity). Such information can be used to more accurately determine useful doses in humans.
  • a therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
  • Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al, 1975, in "The Pharmacological Basis or Therapeutics", Ch. 1 PD.
  • the cell lines that express the insulin receptor may be used to screen for molecules that modulate the tyrosine kinase activity.
  • molecules may include small organic or inorganic compounds, antibodies, peptides, or other molecules that directly activate IRTK by inducing conformations charge and autophosphorylate of the receptor, or indirectly activate IRTK through inhibitor of the IR specific phosphate.
  • Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened in a number of ways.
  • the ability of a test molecule to modulate the activity of IRTK hence signal transduction, may be measured using standard biochemical techniques.
  • Ligand binding to its cellular receptor may, via signal transduction pathways, affect a variety of cellular processes.
  • Cellular processes under the control of insulin signaling pathway may include, but are not limited to, normal cellular functions such as carbohydrate metabolism, proliferation, differentiation, maintenance of cell shape, and adhesion, in addition to abnormal or potentially deleterious processes such as apoptosis, loss of contact inhibition, blocking of differentiation or cell death.
  • the qualitative or quantitative observation and measurement of any of the described cellular processes by techniques known in the art may be advantageously used as a means of scoring for signal transduction in the course of screening.
  • the present invention includes a method for identifying a compound which is capable of modulating insulin receptor-type protein kinase IR-PTK signal transduction, comprising:
  • step (b) incubating the mixture of step (a) for an interval sufficient for the compound to stimulate IRTK enzymatic activity or the signal transduction; (c) measuring the IRTK enzymatic activity or the signal transduction;
  • IR-PTK signal transduction activity may be measured by standard biochemical techniques or by monitoring the cellular processes controlled by the signal.
  • the test molecule is added to a culture medium of IR expressing cells, IR is then immunopurified and IRTK activity measured. Where the test molecule is intended to mimic ligand stimulation, the assay is conducted in the absence of insulin. Where the test molecule is intended to enhance insulin activity, the test is conducted in the presence of insulin.
  • the kinase activity is determined in the presence of ATP and a substrate and results are compared to those obtained for controls i.e., reaction mixtures not exposed to the test molecule.
  • the present invention also includes a method for identifying and isolating a nucleic acid molecule encoding a gene product which is capable of modulating IR-PTK signal transduction, comprising:
  • the above method may further include the step of:
  • step (e) selecting and culturing the cells identified in step (d), recovering the nucleic acid molecule, thereby isolating the nucleic acid molecule.
  • nucleic acid molecule a naturally occurring or recombinantly generated nucleic acid molecule containing a nucleotide sequence operatively associated with an element that controls expression of the nucleotide sequence.
  • An expression library may be created by introducing into host cells a pool of different nucleic acid molecules encoding different gene products. The host cells may be genetically engineered to coexpress IR and other relevant proteins. Such a gene library may be screened by standard biochemical techniques or by monitoring the cellular processes controlled by the signal. This approach is especially useful in identifying other native signaling molecules that are also involved in the signaling pathway.
  • CHO.T cells which overexpress human insulin receptor, were a gift of Dr. R. A. Roth, Stanford University.
  • CHO.T cells (approximately 1.5 x 10-5 cells/well) were cultured in Hams F12 medium supplemented with 10% fetal calf serum, fungizone, penicillin and streptomycin. The 96-well plates were incubated for approximately 24 h at 37°C, which is when the cells reached confluency. The cells were washed with phosphate buffered saline (PBS) three times and then incubated in serum-free medium for 3 h at 37°C. Insulin or test compounds were added to the wells, and the cells were incubated for an additional 20 min at 37°C.
  • PBS phosphate buffered saline
  • the cells were washed three times with PBS and lysates were prepared.
  • the lysates were transferred to a second 96 well plate.
  • the wells of the second plate had been precoated with monoclonal anti-insulin receptor antibody.
  • Antibody was diluted to a final concentration of approximately 4 mcg/mL in 20 mM NaHC03, pH 9.6. Approximately 50 mcL of diluted antibody solution was added to each well.
  • the lysates were incubated for 16 h at 4°C to immunopurify the insulin receptor.
  • the washed plates are incubated for 5 h at 4°C with monoclonal antiphosphotyrosine antibody conjugated to alkaline phosphatase (Transduction Laboratories). The unbound antibody is removed and chromogenic substrate of alkaline phosphotase is added to the wells. Signals are detected at 405 nm with a microtiter plate reader.
  • Compounds identified by the method of Example 1 are formulated into pharmaceutical compositions according to standard methods.
  • the compounds or pharmaceutical compositions are used either alone or in combination with other compounds or compositions for the treatment of animals (including humans) in need of treatment.
  • Conditions requiring treatment include but are not limited to diabetes, obesity, regulation of appetite, congestive heart failure, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.
  • Animals having a condition, the condition being characterized by factors selected from altered levels of insulin or altered activities of insulin, which are treated with compounds or derivatives of compounds identified by the screening method or pharmaceutical compositions comprising the compounds or derivatives of compounds identified by the screening method.
  • CHO.T cells which overexpress human insulin receptor, were a gift of Dr. R. A. Roth, Stanford University.
  • CHO.T cells (approximately 1.5 x 10-5 cells/well) were cultured in Hams F12 medium supplemented with 10% fetal calf serum, fungizone, penicillin and streptomycin. The 96-well plates were incubated for approximately 24 h at 37°C. which is when the cells reached confluency. The cells were washed with phosphate buffered saline (PBS) three times and then incubated in serum-free medium for 3 h at 37°C. Insulin or test compounds were added to the wells, and the cells were incubated for an additional 20 min at 37°C.
  • PBS phosphate buffered saline
  • the cells were washed three times with PBS and lysates were prepared.
  • the lysates were transferred to a second 96 well plate.
  • the wells of the second plate had been precoated with monoclonal anti-insulin receptor antibody.
  • Antibody was diluted to a final concentration of approximately 4 mcg/mL in 20 mM NaHC ⁇ 3, pH 9.6. Approximately 1 0 mcL of diluted antibody solution was added to each well.
  • the lysates were incubated for 16 h at 4°C to immunopurify the insulin receptor.
  • the IRTK To determine the IRTK, twenty microliters of the kinase reaction mixture (50 mM Hepes, pH 7.6, 150 mM NaCl, 5 mM MgCl2, 5 mM MnCl2, 0.1 % Triton X-100, 1 mg/ml poly(Glu:Tyr)(4: l ), 2 ⁇ Ci of carrier-free [ ⁇ -32p]ATP) was added to each well of the 96-well plates and the incubation was continued at 25 °C for 40 min. The reaction was terminated by addition of 50 ⁇ l 100 mM phosphoric acid. The mixture was transferred to Multiscreen PH plates and washed. The radioactivities associated with the wells were determined using a Topcount. The IRTK activities stimulated by test agents were compared to that stimulated by insulin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)

Abstract

L'invention concerne des composés qui sont des agents d'amplification et d'imitation de l'insuline, ainsi que des procédés d'identification de composés imitant et amplifiant l'action de l'insuline.
PCT/US1996/004226 1995-03-31 1996-03-27 Methode d'identification de composes imitant et amplifiant l'action de l'insuline WO1996030762A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP8529629A JPH11503519A (ja) 1995-03-31 1996-03-27 インシュリンの擬似剤及び増強剤のアッセイ
EP96910609A EP0817967A4 (fr) 1995-03-31 1996-03-27 Methode d'identification de composes imitant et amplifiant l'action de l'insuline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41497695A 1995-03-31 1995-03-31
US08/414,976 1995-03-31

Publications (1)

Publication Number Publication Date
WO1996030762A1 true WO1996030762A1 (fr) 1996-10-03

Family

ID=23643820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004226 WO1996030762A1 (fr) 1995-03-31 1996-03-27 Methode d'identification de composes imitant et amplifiant l'action de l'insuline

Country Status (4)

Country Link
EP (1) EP0817967A4 (fr)
JP (1) JPH11503519A (fr)
CA (1) CA2216806A1 (fr)
WO (1) WO1996030762A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032017A3 (fr) * 1997-01-15 1999-02-25 Terrapin Tech Inc Modulateurs de l'activite du recepteur d'insuline
US6660763B2 (en) 1996-11-13 2003-12-09 Sugen, Inc. Bis-indolylquinone compounds
WO2003031472A3 (fr) * 2001-10-09 2004-03-25 Nutricia Nv Sequences d'acides amines insulinomimetiques
US6750240B2 (en) 1996-11-13 2004-06-15 Sugen, Inc. Methods of using bis-indolylquinones
US6884597B1 (en) 1998-01-20 2005-04-26 Medical & Biological Laboratories, Co., Ltd. Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes
USRE38915E1 (en) 1997-01-15 2005-12-06 Telik, Inc. Nonpeptide insulin receptor agonists

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055664A2 (fr) * 2001-01-12 2002-07-18 Exelixis, Inc. Modulation de la signalisation du recepteur de l'insuline

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536517A (en) * 1983-04-25 1985-08-20 American Cyanamid Company Method of treating diabetes mellitus using arylglyoxals
US5405855A (en) * 1993-12-23 1995-04-11 Andrulis Pharmaceuticals Corp. Treatment of insulin resistant diabetes with thalidomine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019570A1 (fr) * 1994-01-14 1995-07-20 Genentech, Inc. Antagonistes de l'inhibiteur de l'activite tyrosine kinase du recepteur de l'insuline
US5861266A (en) * 1994-02-28 1999-01-19 New York University Treatment of diabetes mellitus and insulin receptor signal transduction
WO1995023231A1 (fr) * 1994-02-28 1995-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Lignees cellulaires destinees a l'identification de substances affectant la transduction du signal induit par le recepteur d'insuline
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536517A (en) * 1983-04-25 1985-08-20 American Cyanamid Company Method of treating diabetes mellitus using arylglyoxals
US5405855A (en) * 1993-12-23 1995-04-11 Andrulis Pharmaceuticals Corp. Treatment of insulin resistant diabetes with thalidomine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL JOURNAL, Vol. 268, issued 1990, BRINDLE et al., "Anti-(Insulin Receptor) Monoclonal Antibody-Stimulated Tyrosine Phosphorylation in Cells Transfected with Human Insulin Receptor cDNA", pages 615-620. *
See also references of EP0817967A4 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 16, issued 05 June 1990, G. STEELE-PERKINS et al., "Insulin-Mimetic Anti-Insulin Receptor Monoclonal Antibodies Stimulate Receptor Kinase Activity in Intact Cells", pages 9458-9463. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660763B2 (en) 1996-11-13 2003-12-09 Sugen, Inc. Bis-indolylquinone compounds
US6750240B2 (en) 1996-11-13 2004-06-15 Sugen, Inc. Methods of using bis-indolylquinones
WO1998032017A3 (fr) * 1997-01-15 1999-02-25 Terrapin Tech Inc Modulateurs de l'activite du recepteur d'insuline
USRE38915E1 (en) 1997-01-15 2005-12-06 Telik, Inc. Nonpeptide insulin receptor agonists
USRE39866E1 (en) 1997-01-15 2007-10-02 Telik, Inc. Nonpeptide insulin receptor agonists
US6884597B1 (en) 1998-01-20 2005-04-26 Medical & Biological Laboratories, Co., Ltd. Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes
WO2003031472A3 (fr) * 2001-10-09 2004-03-25 Nutricia Nv Sequences d'acides amines insulinomimetiques

Also Published As

Publication number Publication date
JPH11503519A (ja) 1999-03-26
EP0817967A1 (fr) 1998-01-14
EP0817967A4 (fr) 2000-05-17
CA2216806A1 (fr) 1996-10-03

Similar Documents

Publication Publication Date Title
Ross et al. Chemistry and biochemistry of type 2 diabetes
Gottschalk et al. Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus
Cui et al. The role of AMPK in macrophage metabolism, function and polarisation
Hajduch et al. Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle
Rockey The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide
Huang et al. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons
US7344843B2 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
WO1996040109A1 (fr) Procedes d'inhibition de l'activite de phosphatase, et de traitement de pathologies associees a l'aide de naphtopyrones et de leurs derives
Qu et al. Theaflavin promotes mitochondrial abundance and glucose absorption in myotubes by activating the CaMKK2-AMPK signal axis via calcium-ion influx
Beg et al. PPP2R5B, a regulatory subunit of PP2A, contributes to adipocyte insulin resistance
US5861266A (en) Treatment of diabetes mellitus and insulin receptor signal transduction
RU2417078C2 (ru) Новое применение агонистов печеночного рецептора х
WO1996030762A1 (fr) Methode d'identification de composes imitant et amplifiant l'action de l'insuline
Gezginci-Oktayoglu et al. 4-Methlycatechol prevents NGF/p75NTR-mediated apoptosis via NGF/TrkA system in pancreatic β cells
Small et al. Phenotypic screening for small molecules that protect β-cells from glucolipotoxicity
SENTHIL et al. Angiotensin II inhibits insulin-stimulated phosphorylation of eukaryotic initiation factor 4E-binding protein-1 in proximal tubular epithelial cells
US20020022023A1 (en) Treatment of diabetes mellitus and insulin receptor signal transduction
Yamaguchi et al. The behavior of dihydropyrazine with DNA strand-breakage activity in vivo
Andreozzi et al. Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo
US20120264796A1 (en) Methods for modulating circadian rhythms
US20030095983A1 (en) Use of corticotroph-derived glycoprotein hormone to induce lipolysis
AU2005251741B2 (en) Insulin-independent, bone morphogenetic protein (BMP)-mediated uptake of blood glucose by peripheral cells and tissues
Yu et al. The upregulating effect of insulin and vanadate on cell surface insulin receptors in rat adipocytes is modulated by glucose and energy availability
US7276342B2 (en) Xobesin agonists and antagonists for the treatment of metabolic disorders
Chao et al. Interleukin-4 restores insulin sensitivity in insulin-resistant osteoblasts by increasing the expression of insulin receptor substrate 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1996910609

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 913917

Date of ref document: 19970923

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2216806

Country of ref document: CA

Ref country code: CA

Ref document number: 2216806

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 529629

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996910609

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996910609

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载